ArticleArthritis care & research2026
Prevalence of Arthritis-Attributable Work Limitations Among Adults Aged 18-64 Years With Arthritis: United States, 2023.
Article in Arthritis care & research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectiveThis cross-sectional study estimates national prevalence of arthritis-attributable work limitations (AAWL), describes differences in prevalence of AAWL by selected demographic and health characteristics, and assesses progress toward the AAWL Healthy People 2030 objective from 2019 to 2023.
methodsUsing data from the 2023 National Health Interview Survey, unadjusted and age-standardized prevalence of AAWL were estimated overall and by selected demographic and health characteristics. Data were age-standardized using four age groups (18-34, 35-44, 45-54, 55-64 years). t tests assessed differences by population subgroup and by data year (2019 and 2023). Age-standardized prevalence was reported when making comparisons.
resultsIn 2023, the age-standardized prevalence of AAWL among US adults with arthritis aged 18 to 64 years was 38.8% (95% confidence interval 35.6-42.2). AAWL was significantly higher among Hispanic (50.1%) and non-Hispanic American Indian and Alaska Native adults (55.9%) compared to non-Hispanic White adults (35.6%). AAWL was higher among those with a disability (62.1%) than without (33.5%), those unable to work or who were disabled (61.8%) than employed/self-employed (32.2%), and veterans (52.5%) than nonveterans (37.8%). Respondents rating their health status as poor/fair (61.1%) or good (33.0%) had higher prevalence of AAWL than those with excellent/very good health status (23.9%). Adults with difficulty walking or climbing stairs (68.5%) had higher prevalence of AAWL compared to adults without difficulty (35.1%). The prevalence of AAWL during 2019 (38.1%) and 2023 (38.8%) was not significantly different.
conclusionMore than one-third of US adults aged 18 to 64 years with arthritis report AAWL. Promoting arthritis-appropriate evidence-based interventions is important for achieving the Healthy People 2030 AAWL objective.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.